|
Setting (ref)
|
Sample Size
|
Statin Use
|
ACE InhibitorUse
|
Beta-blockerUse
|
Antiplatelet Use
|
Current Smokers
|
% with cholesterol at or below target*
|
|---|
|
Audits from General Practices:
|
|
Canada (42)
|
4315
|
38%
|
NR
|
NR
|
53%
|
25%
|
14%
|
|
Canada (43)
|
NR
|
NR
|
NR
|
NR
|
54%
|
NR
|
NR
|
|
USA (46)
|
11 745
|
NR
|
NR
|
21%
|
NR
|
NR
|
NR
|
|
UK (41)
|
1921
|
NR
|
10%
|
32%
|
63%
|
18%
|
17%
|
|
UK (44)
|
24 431
|
16%
|
13%
|
22%
|
50%
|
24%
|
56%
|
|
Canada (49)
|
3721
|
100%
|
NR
|
NR
|
NR
|
17%
|
73%
|
|
International REACH Registry (50)
|
40 258
|
76%
|
51%
|
63%
|
86%
|
13%
|
NR
|
|
Audits in patients discharged after acute myocardial infarction or coronary artery bypass surgery:
|
|
USA (39)
|
201 752
|
NR
|
30%
|
34%
|
83%
|
NR
|
NR
|
|
USA (37)
|
1710
|
12%
|
NR
|
44%
|
53%
|
NR
|
NR
|
|
USA (38)
|
622
|
37%
|
NR
|
23%
|
46%
|
25%
|
15%
|
|
USA (45)
|
190 015
|
NR
|
31%
|
NR
|
NR
|
NR
|
NR
|
|
USA (47)
|
25 000
|
NR
|
NR
|
NR
|
81%
|
NR
|
NR
|
|
Europe (40)
|
3379
|
58%
|
43%
|
66%
|
84%
|
21%
|
41%
|
|
Ontario(48)
|
9667
|
40%
|
65%
|
68%
|
NR
|
NR
|
NR
|
|
Quebec(48)
|
4790
|
43%
|
57%
|
68%
|
NR
|
NR
|
NR
|
|
British Columbia(48)
|
2570
|
42%
|
58%
|
61%
|
NR
|
NR
|
NR
|
|
Nova Scotia(48)
|
761
|
36%
|
58%
|
83%
|
NR
|
NR
|
NR
|
|
Alberta (APPROACH patients)**
|
5104
|
34%
|
39%
|
61%
|
81%
|
NR
|
NR
|
- Note that while the general practice audits represent cross-sectional data at varying times after the diagnosis of CAD, the audits in patients discharged after acute MI generally represent prescribing data between 90 days and 120 days after MI.
- * Target cholesterol defined as LDL cholesterol ≤ 2.6 mmol/L or total cholesterol ≤ 5.0 mmol/L.
- ** Medications in use at the time of the cardiac catheterization (no data available on prescriptions in follow-up). [Colleen Norris, personal communication, August 2003]
